Clinical Trial

A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 in patients with advanced triple-negative breast cancer (TNBC) who have progressed after prior therapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-27; most recent amendment 2026-02-09.
Status change: Not Yet Recruiting → Recruiting 2026-02-09
Trial Details
NCT Number NCT07208149
Lead Sponsor Shenzhen Majory Biotechnology Co., Ltd.
Conditions Triple-Negative Breast Cancer (TNBC)
Enrollment 42 participants
Start Date 2026-01-29
Primary Completion 2028-09-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-12